Pharmaceutical Business Review
Return to: PBR Home | Suppliers

Minding your Caps and Tails – Considerations for Functional mRNA Synthesis

Published 09 November 2015 | By New England Biolabs

Applications of synthetic mRNA have grown and become considerably diversified in recent years. Examples include the generation of pluripotent stem cells (1-3), vaccines and therapeutics (4), and CRISPR/Cas9 genome editing applications (5-7). The basic requirements for a functional mRNA - a 7-methylguanylate cap at the 5´ end and a poly(A) tail at the 3´ end - must be added in order to obtain efficient translation by eukaryotic cells. Additional considerations can include the incorporation of modified bases, modified cap structures and polyadenylation strategies. Strategies for in vitro synthesis of mRNA may also vary according to the desired scale of synthesis. This article discusses options for selection of reagents and the extent to which it influences synthesized mRNA functionality.

Available Downloads

Minding your Caps and Tails – Considerations for Functional mRNA Synthesis